Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients

Regorafenib was approved as third-line therapy for advanced Gastrointestinal Stromal Tumour (GIST) at a starting dose of 160 mg daily 3 weeks on, 1 week off, based on improvement in progression free survival over placebo (4.8 vs. 0.9 months), but the response rate was low at 4.5%. Given the high tox...

Descripción completa

Detalles Bibliográficos
Autores principales: Schvartsman, Gustavo, Wagner, Michael J., Amini, Behrang, Zobniw, Chrystia M., Trinh, Van Anh, Barbo, Andrea G., Lin, Heather Y., Wang, Wei-Lien, Conley, Anthony Paul, Ravi, Vinod, Araujo, Dejka M., Zarzour, Maria Alejandra, Benjamin, Robert S., Patel, Shreyaskumar, Somaiah, Neeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573380/
https://www.ncbi.nlm.nih.gov/pubmed/28842575
http://dx.doi.org/10.1038/s41598-017-09132-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573380/
https://www.ncbi.nlm.nih.gov/pubmed/28842575
http://dx.doi.org/10.1038/s41598-017-09132-1

Ejemplares similares